Dubinett S M, Huang M, Dhanani S, Economou J S, Wang J, Lee P, Sharma S, Dougherty G J, McBride W H
Pulmonary Immunology Laboratory, UCLA School of Medicine, USA.
J Natl Cancer Inst. 1995 Apr 19;87(8):593-7. doi: 10.1093/jnci/87.8.593.
Cytokine genes encode proteins that modulate immune system responses. Modification of tumor cells by the introduction of cytokine genes has been used as a strategy to augment host immunity. Interleukin 7 (IL-7) gene transfer enhances the immune response to tumor cells and can result in tumor regression. Transforming growth factor-beta 1 (TGF-beta 1) is a potent immunosuppressive cytokine produced by many tumors. We have previously reported that recombinant IL-7 decreases the expression of TGF-beta 1 by murine macrophages.
This study investigates the inhibition of tumor-derived TGF-beta 1 production as a possible mechanism for the enhanced antitumor immunity that accompanies IL-7 gene transfer.
A fibrosarcoma cell line (FSA-JmIL-7) genetically modified to produce IL-7 was used to evaluate the effects of IL-7 on tumor production of TGF-beta 1. The control cell line (FSA-Jneo) originated from the same parental fibrosarcoma cell line (FSA) and was produced by transduction with the same retroviral vector without the IL-7 gene. FSA-Jneo and FSA-JmIL-7 tumor cells were evaluated for the expression of TGF-beta 1 messenger RNA (mRNA). To determine if the observed change in TGF-beta 1 mRNA was associated with an alteration in protein secretion, we compared supernatants from tumor cell cultures for TGF-beta 1 production. Specific anti-TGF-beta 1 monoclonal antibody (MAb) was used to confirm the role of TGF-beta 1 in these assays.
Compared with FSA parental and FSA-Jneo cells, FSA-JmIL-7 cells expressed TGF-beta 1 mRNA at a lower level. Compared with supernatants from FSA-Jneo cells, FSA-JmIL-7 supernatants contained consistently lower levels of TGF-beta 1 activity (P < .05). In addition, FSA-Jneo supernatants suppressed lymphocyte proliferation to a significantly greater degree than supernatants from FSA-JmIL-7 cells (P < .05). Studies with anti-TGF-beta 1 MAb added to the supernatants confirmed the role of TGF-beta 1 in inhibition of lymphocyte proliferation.
These findings suggest that IL-7 gene transfer inhibits the production of TGF-beta 1 by tumor cells and thus may enhance the efficacy of the host's antitumor immune response.
The regulation of endogenous tumor-derived cytokines in response to cytokine gene transfer may contribute to altered immune responses in the tumor microenvironment and thus may be an important additional parameter to assess in gene therapy.
细胞因子基因编码调节免疫系统反应的蛋白质。通过引入细胞因子基因对肿瘤细胞进行改造已被用作增强宿主免疫力的一种策略。白细胞介素7(IL-7)基因转移可增强对肿瘤细胞的免疫反应,并可导致肿瘤消退。转化生长因子-β1(TGF-β1)是一种由许多肿瘤产生的强效免疫抑制细胞因子。我们之前曾报道,重组IL-7可降低小鼠巨噬细胞中TGF-β1的表达。
本研究调查抑制肿瘤来源的TGF-β1产生是否是伴随IL-7基因转移的增强抗肿瘤免疫力的可能机制。
使用经基因改造以产生IL-7的纤维肉瘤细胞系(FSA-JmIL-7)来评估IL-7对肿瘤产生TGF-β1的影响。对照细胞系(FSA-Jneo)源自同一亲本纤维肉瘤细胞系(FSA),通过用不含IL-7基因的相同逆转录病毒载体转导产生。对FSA-Jneo和FSA-JmIL-7肿瘤细胞进行TGF-β1信使核糖核酸(mRNA)表达评估。为确定观察到的TGF-β1 mRNA变化是否与蛋白质分泌改变有关,我们比较了肿瘤细胞培养上清液中TGF-β1的产生情况。使用特异性抗TGF-β1单克隆抗体(MAb)来证实TGF-β1在这些实验中的作用。
与FSA亲本细胞和FSA-Jneo细胞相比,FSA-JmIL-7细胞中TGF-β1 mRNA的表达水平较低。与FSA-Jneo细胞的上清液相比,FSA-JmIL-7上清液中TGF-β1活性水平始终较低(P < 0.05)。此外,FSA-Jneo上清液对淋巴细胞增殖的抑制程度明显大于FSA-JmIL-7细胞的上清液(P < 0.05)。向上清液中添加抗TGF-β1 MAb的研究证实了TGF-β1在抑制淋巴细胞增殖中的作用。
这些发现表明,IL-7基因转移可抑制肿瘤细胞产生TGF-β1,从而可能增强宿主抗肿瘤免疫反应的功效。
响应细胞因子基因转移对内源性肿瘤来源细胞因子的调节可能有助于改变肿瘤微环境中的免疫反应,因此可能是基因治疗中一个重要的额外评估参数。